QIAGEN N.V. (QGEN) Fundamental Analysis & Valuation

NYSE:QGEN • NL0015002SN0

Current stock price

39.78 USD
+0.29 (+0.73%)
At close:
39.78 USD
0 (0%)
After Hours:

This QGEN fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

7

1. QGEN Profitability Analysis

1.1 Basic Checks

  • QGEN had positive earnings in the past year.
  • QGEN had a positive operating cash flow in the past year.
  • Each year in the past 5 years QGEN has been profitable.
  • Each year in the past 5 years QGEN had a positive operating cash flow.
QGEN Yearly Net Income VS EBIT VS OCF VS FCFQGEN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M 400M 600M

1.2 Ratios

  • QGEN has a better Return On Assets (6.75%) than 83.93% of its industry peers.
  • The Return On Equity of QGEN (11.25%) is better than 82.14% of its industry peers.
  • QGEN's Return On Invested Capital of 7.23% is fine compared to the rest of the industry. QGEN outperforms 78.57% of its industry peers.
Industry RankSector Rank
ROA 6.75%
ROE 11.25%
ROIC 7.23%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
QGEN Yearly ROA, ROE, ROICQGEN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5 10 15

1.3 Margins

  • With an excellent Profit Margin value of 20.33%, QGEN belongs to the best of the industry, outperforming 94.64% of the companies in the same industry.
  • QGEN's Profit Margin has been stable in the last couple of years.
  • QGEN has a Operating Margin of 25.69%. This is amongst the best in the industry. QGEN outperforms 96.43% of its industry peers.
  • QGEN's Operating Margin has declined in the last couple of years.
  • With an excellent Gross Margin value of 62.97%, QGEN belongs to the best of the industry, outperforming 83.93% of the companies in the same industry.
  • QGEN's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 25.69%
PM (TTM) 20.33%
GM 62.97%
OM growth 3Y-2.56%
OM growth 5Y-2.83%
PM growth 3Y0.95%
PM growth 5Y1.14%
GM growth 3Y-1.29%
GM growth 5Y-1.16%
QGEN Yearly Profit, Operating, Gross MarginsQGEN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. QGEN Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so QGEN is destroying value.
  • QGEN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
QGEN Yearly Shares OutstandingQGEN Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M
QGEN Yearly Total Debt VS Total AssetsQGEN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

2.2 Solvency

  • QGEN has an Altman-Z score of 3.45. This indicates that QGEN is financially healthy and has little risk of bankruptcy at the moment.
  • With a decent Altman-Z score value of 3.45, QGEN is doing good in the industry, outperforming 71.43% of the companies in the same industry.
  • The Debt to FCF ratio of QGEN is 3.70, which is a good value as it means it would take QGEN, 3.70 years of fcf income to pay off all of its debts.
  • QGEN has a better Debt to FCF ratio (3.70) than 76.79% of its industry peers.
  • A Debt/Equity ratio of 0.44 indicates that QGEN is not too dependend on debt financing.
  • QGEN has a Debt to Equity ratio (0.44) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.44
Debt/FCF 3.7
Altman-Z 3.45
ROIC/WACC0.81
WACC8.9%
QGEN Yearly LT Debt VS Equity VS FCFQGEN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B

2.3 Liquidity

  • QGEN has a Current Ratio of 3.90. This indicates that QGEN is financially healthy and has no problem in meeting its short term obligations.
  • QGEN's Current ratio of 3.90 is fine compared to the rest of the industry. QGEN outperforms 66.07% of its industry peers.
  • QGEN has a Quick Ratio of 3.31. This indicates that QGEN is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of QGEN (3.31) is better than 66.07% of its industry peers.
Industry RankSector Rank
Current Ratio 3.9
Quick Ratio 3.31
QGEN Yearly Current Assets VS Current LiabilitesQGEN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. QGEN Growth Analysis

3.1 Past

  • QGEN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 10.63%, which is quite good.
  • Measured over the past 5 years, QGEN shows a small growth in Earnings Per Share. The EPS has been growing by 1.64% on average per year.
  • QGEN shows a small growth in Revenue. In the last year, the Revenue has grown by 5.65%.
  • Measured over the past years, QGEN shows a small growth in Revenue. The Revenue has been growing by 2.25% on average per year.
EPS 1Y (TTM)10.63%
EPS 3Y-0.54%
EPS 5Y1.64%
EPS Q2Q%1.64%
Revenue 1Y (TTM)5.65%
Revenue growth 3Y-0.81%
Revenue growth 5Y2.25%
Sales Q2Q%3.69%

3.2 Future

  • The Earnings Per Share is expected to grow by 7.28% on average over the next years.
  • Based on estimates for the next years, QGEN will show a small growth in Revenue. The Revenue will grow by 7.75% on average per year.
EPS Next Y5.2%
EPS Next 2Y7.62%
EPS Next 3Y8.36%
EPS Next 5Y7.28%
Revenue Next Year6.7%
Revenue Next 2Y6.18%
Revenue Next 3Y6.14%
Revenue Next 5Y7.75%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
QGEN Yearly Revenue VS EstimatesQGEN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 1B 2B 3B
QGEN Yearly EPS VS EstimatesQGEN Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 1 2 3

More info and screens

Find the best growth stocksShow best growing peers

6

4. QGEN Valuation Analysis

4.1 Price/Earnings Ratio

  • QGEN is valuated correctly with a Price/Earnings ratio of 16.11.
  • QGEN's Price/Earnings ratio is rather cheap when compared to the industry. QGEN is cheaper than 91.07% of the companies in the same industry.
  • When comparing the Price/Earnings ratio of QGEN to the average of the S&P500 Index (25.54), we can say QGEN is valued slightly cheaper.
  • A Price/Forward Earnings ratio of 15.29 indicates a correct valuation of QGEN.
  • Based on the Price/Forward Earnings ratio, QGEN is valued cheaply inside the industry as 87.50% of the companies are valued more expensively.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 22.70, QGEN is valued a bit cheaper.
Industry RankSector Rank
PE 16.11
Fwd PE 15.29
QGEN Price Earnings VS Forward Price EarningsQGEN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • 91.07% of the companies in the same industry are more expensive than QGEN, based on the Enterprise Value to EBITDA ratio.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of QGEN indicates a rather cheap valuation: QGEN is cheaper than 87.50% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 18.33
EV/EBITDA 11.54
QGEN Per share dataQGEN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
  • QGEN has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)3.1
PEG (5Y)9.84
EPS Next 2Y7.62%
EPS Next 3Y8.36%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

3

5. QGEN Dividend Analysis

5.1 Amount

  • With a yearly dividend of 0.65%, QGEN is not a good candidate for dividend investing.
  • QGEN's Dividend Yield is rather good when compared to the industry average which is at 0.12. QGEN pays more dividend than 94.64% of the companies in the same industry.
  • Compared to an average S&P500 Dividend Yield of 1.89, QGEN's dividend is way lower than the S&P500 average.
Industry RankSector Rank
Dividend Yield 0.65%

5.2 History

  • QGEN does not have a reliable dividend history as it only pays dividend since a couple or years.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
QGEN Yearly Dividends per shareQGEN Yearly Dividends per shareYearly Dividends per share 2024 2025 0.2 0.4 0.6 0.8 1

5.3 Sustainability

  • QGEN pays out 12.77% of its income as dividend. This is a sustainable payout ratio.
DP12.77%
EPS Next 2Y7.62%
EPS Next 3Y8.36%
QGEN Yearly Income VS Free CF VS DividendQGEN Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M 400M
QGEN Dividend Payout.QGEN Dividend Payout, showing the Payout Ratio.QGEN Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

QGEN Fundamentals: All Metrics, Ratios and Statistics

QIAGEN N.V.

NYSE:QGEN (3/24/2026, 5:46:03 PM)

After market: 39.78 0 (0%)

39.78

+0.29 (+0.73%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)02-05
Earnings (Next)05-05
Inst Owners74.12%
Inst Owner Change-99.66%
Ins Owners0.44%
Ins Owner ChangeN/A
Market Cap8.20B
Revenue(TTM)2.09B
Net Income(TTM)424.88M
Analysts71.67
Price Target55.35 (39.14%)
Short Float %3.33%
Short Ratio2.61
Dividend
Industry RankSector Rank
Dividend Yield 0.65%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP12.77%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.46%
Min EPS beat(2)-3.03%
Max EPS beat(2)2.11%
EPS beat(4)2
Avg EPS beat(4)1.12%
Min EPS beat(4)-3.03%
Max EPS beat(4)7.8%
EPS beat(8)5
Avg EPS beat(8)1.49%
EPS beat(12)7
Avg EPS beat(12)1.45%
EPS beat(16)11
Avg EPS beat(16)3.7%
Revenue beat(2)0
Avg Revenue beat(2)-0.52%
Min Revenue beat(2)-0.72%
Max Revenue beat(2)-0.31%
Revenue beat(4)1
Avg Revenue beat(4)0.07%
Min Revenue beat(4)-0.72%
Max Revenue beat(4)1.43%
Revenue beat(8)1
Avg Revenue beat(8)-0.61%
Revenue beat(12)1
Avg Revenue beat(12)-0.7%
Revenue beat(16)5
Avg Revenue beat(16)-0.05%
PT rev (1m)1.17%
PT rev (3m)7.13%
EPS NQ rev (1m)-3.35%
EPS NQ rev (3m)-5.36%
EPS NY rev (1m)-3.43%
EPS NY rev (3m)0.35%
Revenue NQ rev (1m)-1.57%
Revenue NQ rev (3m)-1.73%
Revenue NY rev (1m)0.4%
Revenue NY rev (3m)0.53%
Valuation
Industry RankSector Rank
PE 16.11
Fwd PE 15.29
P/S 3.92
P/FCF 18.33
P/OCF 12.53
P/B 2.17
P/tB 11.86
EV/EBITDA 11.54
EPS(TTM)2.47
EY6.21%
EPS(NY)2.6
Fwd EY6.54%
FCF(TTM)2.17
FCFY5.46%
OCF(TTM)3.18
OCFY7.98%
SpS10.14
BVpS18.33
TBVpS3.35
PEG (NY)3.1
PEG (5Y)9.84
Graham Number31.92
Profitability
Industry RankSector Rank
ROA 6.75%
ROE 11.25%
ROCE 9.28%
ROIC 7.23%
ROICexc 8.92%
ROICexgc 26.15%
OM 25.69%
PM (TTM) 20.33%
GM 62.97%
FCFM 21.4%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-2.56%
OM growth 5Y-2.83%
PM growth 3Y0.95%
PM growth 5Y1.14%
GM growth 3Y-1.29%
GM growth 5Y-1.16%
F-Score6
Asset Turnover0.33
Health
Industry RankSector Rank
Debt/Equity 0.44
Debt/FCF 3.7
Debt/EBITDA 2.26
Cap/Depr 106.91%
Cap/Sales 9.91%
Interest Coverage 250
Cash Conversion 89.55%
Profit Quality 105.25%
Current Ratio 3.9
Quick Ratio 3.31
Altman-Z 3.45
F-Score6
WACC8.9%
ROIC/WACC0.81
Cap/Depr(3y)90.15%
Cap/Depr(5y)87.64%
Cap/Sales(3y)8.95%
Cap/Sales(5y)8.6%
Profit Quality(3y)264.36%
Profit Quality(5y)202.24%
High Growth Momentum
Growth
EPS 1Y (TTM)10.63%
EPS 3Y-0.54%
EPS 5Y1.64%
EPS Q2Q%1.64%
EPS Next Y5.2%
EPS Next 2Y7.62%
EPS Next 3Y8.36%
EPS Next 5Y7.28%
Revenue 1Y (TTM)5.65%
Revenue growth 3Y-0.81%
Revenue growth 5Y2.25%
Sales Q2Q%3.69%
Revenue Next Year6.7%
Revenue Next 2Y6.18%
Revenue Next 3Y6.14%
Revenue Next 5Y7.75%
EBIT growth 1Y8.48%
EBIT growth 3Y-3.35%
EBIT growth 5Y-0.65%
EBIT Next Year39.63%
EBIT Next 3Y17.72%
EBIT Next 5Y11.87%
FCF growth 1Y-10.97%
FCF growth 3Y-7.55%
FCF growth 5Y23.83%
OCF growth 1Y-2.85%
OCF growth 3Y-2.92%
OCF growth 5Y7.4%

QIAGEN N.V. / QGEN Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for QIAGEN N.V.?

ChartMill assigns a fundamental rating of 6 / 10 to QGEN.


Can you provide the valuation status for QIAGEN N.V.?

ChartMill assigns a valuation rating of 6 / 10 to QIAGEN N.V. (QGEN). This can be considered as Fairly Valued.


What is the profitability of QGEN stock?

QIAGEN N.V. (QGEN) has a profitability rating of 7 / 10.


What is the earnings growth outlook for QIAGEN N.V.?

The Earnings per Share (EPS) of QIAGEN N.V. (QGEN) is expected to grow by 5.2% in the next year.


Can you provide the dividend sustainability for QGEN stock?

The dividend rating of QIAGEN N.V. (QGEN) is 3 / 10 and the dividend payout ratio is 12.77%.